Skip to main content

ADVERTISEMENT

Peter B. Berger, MD

08/01/2008
There have been rapid improvements in percutaneous coronary intervention since its introduction. However, complex lesions unsuitable for routine angioplasty continue to pose a significant problem. A number of alternative devices have been...
There have been rapid improvements in percutaneous coronary intervention since its introduction. However, complex lesions unsuitable for routine angioplasty continue to pose a significant problem. A number of alternative devices have been...
There have been rapid...
08/01/2008
Journal of Invasive Cardiology
07/31/2013
I asked my expert cath lab colleagues to weigh in on this issue with 3 quick answers on whether forced reduction of D2B time is 1) beneficial for the patient or 2) the hospital or 3) the interventionalist, and if you have time, a short...
I asked my expert cath lab colleagues to weigh in on this issue with 3 quick answers on whether forced reduction of D2B time is 1) beneficial for the patient or 2) the hospital or 3) the interventionalist, and if you have time, a short...
I asked my expert cath lab...
07/31/2013
Cath Lab Digest
Commentary
08/01/2008
Diabetes mellitus is a public health problem of increasing importance in both the developed and developing worlds.1 The prevalence of obesity, the metabolic syndrome, and in particular diabetes, continues to increase; the impact on present...
Diabetes mellitus is a public health problem of increasing importance in both the developed and developing worlds.1 The prevalence of obesity, the metabolic syndrome, and in particular diabetes, continues to increase; the impact on present...
Diabetes mellitus is a public...
08/01/2008
Journal of Invasive Cardiology
Case Report
08/01/2008
Eptifibatide, a cyclic heptapeptide inhibitor of the platelet membrane glycoprotein (GP) IIb/IIIa receptor, reduces the incidence of ischemic complications when administered at the time of percutaneous coronary intervention (PC I).1 Major...
Eptifibatide, a cyclic heptapeptide inhibitor of the platelet membrane glycoprotein (GP) IIb/IIIa receptor, reduces the incidence of ischemic complications when administered at the time of percutaneous coronary intervention (PC I).1 Major...
Eptifibatide, a cyclic...
08/01/2008
Journal of Invasive Cardiology
Original Contribution
08/01/2008
When clopidogrel is added to background aspirin therapy, it reduces the composite of cardiovascular death, myocardial infarction (MI) or stroke in patients with acute coronary syndromes (ACS)1 or percutaneous revascularization.2 The most...
When clopidogrel is added to background aspirin therapy, it reduces the composite of cardiovascular death, myocardial infarction (MI) or stroke in patients with acute coronary syndromes (ACS)1 or percutaneous revascularization.2 The most...
When clopidogrel is added to...
08/01/2008
Journal of Invasive Cardiology
Original Contribution
05/04/2009
ABSTRACT: Background. The frequency of ad hoc percutaneous coronary intervention (PCI) varies among institutions and regions of the country. It is unclear what factors limit use of the ad hoc strategy. Objective. To define factors which limit...
ABSTRACT: Background. The frequency of ad hoc percutaneous coronary intervention (PCI) varies among institutions and regions of the country. It is unclear what factors limit use of the ad hoc strategy. Objective. To define factors which limit...
ABSTRACT: Background. The...
05/04/2009
Journal of Invasive Cardiology
Original Contribution
02/02/2010
ABSTRACT: Objective. To examine the 1-year safety and clinical outcomes associated with the post-marketing early unselected use of sirolimus-eluting stents (SES) in the United States. Background. The safety and effectiveness of SES has been...
ABSTRACT: Objective. To examine the 1-year safety and clinical outcomes associated with the post-marketing early unselected use of sirolimus-eluting stents (SES) in the United States. Background. The safety and effectiveness of SES has been...
ABSTRACT: Objective. To examine...
02/02/2010
Journal of Invasive Cardiology
Original Contribution
05/26/2011
Journal of Invasive Cardiology
Clinical Editor's Corner
07/26/2016
In this “Conversation in Cardiology”, Dr. Ted Feldman from Evanston Hospital, Evanston, Illinois, asks, “Is the availability of Impella a requirement for every STEMI [ST-elevation myocardial infarction] program (even in lower volume programs...
In this “Conversation in Cardiology”, Dr. Ted Feldman from Evanston Hospital, Evanston, Illinois, asks, “Is the availability of Impella a requirement for every STEMI [ST-elevation myocardial infarction] program (even in lower volume programs...
In this “Conversation in...
07/26/2016
Cath Lab Digest
Original Contribution
09/15/2015
The authors present a retrospective analysis to determine the safety and efficacy of administering prasugrel at the time of percutaneous coronary intervention (PCI), and switching to clopidogrel, without reloading. 
The authors present a retrospective analysis to determine the safety and efficacy of administering prasugrel at the time of percutaneous coronary intervention (PCI), and switching to clopidogrel, without reloading. 
The authors present a...
09/15/2015
Journal of Invasive Cardiology